Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PD of Tegoprazan in Healthy Males
NCT03378284Phase 1Completed
- Sponsor
- HK inno.N Corporation
- Start
- Dec 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tegoprazan in gastroesophageal reflux disease (GERD) and gastric ulcer (2 arms), sponsored by HK inno.N Corporation. Primary endpoints: Gastric pH up to 7 days and Serum gastrin concentration up to 9 days. Started Dec 2017; status: completed.
02
Drugs
tegoprazan
03
Conditions
gastroesophageal reflux disease (GERD)gastric ulcer
Beyond the preview
Go deeper on NCT03378284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03378284.